Percheron Therapeutics Limited

Percheron Therapeutics Limited

0.00
USD
0.00
(0.00%)
0.00EPS
3.31MMarket Cap
Feb 24Next Earn

Total Valuation

USD

As of June 30, 2026, Percheron Therapeutics Ltd carries a market capitalization of 3.31M, placing it among publicly traded companies globally. Its enterprise value stands at 522,760.35, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.31M
Enterprise Value522,760.35

Important Dates

Percheron Therapeutics Ltd's next confirmed earnings release is scheduled for February 24, 2027.

Earnings Date2/24/2027

Share Statistics

As of June 30, 2026, Percheron Therapeutics Ltd has 1.17B shares outstanding.

Shares Outstanding1.17B

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio0.63
P/TBV Ratio1.03

Financial Position

As of June 30, 2026, Percheron Therapeutics Ltd maintains a current ratio of 7.64, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.37, indicating conservative leverage, while an interest coverage ratio of -352.03 demonstrates limited ability to service its debt obligations.

Current Ratio7.64
Quick Ratio7.24
Debt / Equity0.37
Debt / EBITDA-0.01
Interest Coverage-352.03

Financial Efficiency

Over the twelve months ended June 30, 2026, Percheron Therapeutics Ltd posted a negative return on equity (ROE) of -54.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.39, reflecting losses generated across the asset base.

Return on Equity (ROE)-54.66
Return on Assets (ROA)-46.39

Stock Price Statistics

USD

As of the close on July 27, 2026, Percheron Therapeutics Ltd's stock has declined approximately 38.40% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.10.

52-Week Price Change-38.40%
50-Day Moving Average0.03
200-Day Moving Average0.10

Income Statement

USD

These figures cover the twelve months ended June 30, 2026. EBITDA reached -3.74M, while operating income came in at -3.89M.

Operating Income-3.89M
Pretax Income-3.32M
Net Income-3.32M
EBITDA-3.74M
EBIT-3.89M

Balance Sheet

USD

As of June 30, 2026, Percheron Therapeutics Ltd holds 2.80M in cash and equivalents against 19,229.07 in total debt, resulting in a net debt position of -2.80M. Total book value stands at 5.21M, with working capital of 3.18M providing operational flexibility.

Cash & Cash Equivalents2.80M
Total Debt19,229.07
Net Debt-2.80M
Equity (Book Value)5.21M
Working Capital3.18M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-2.14M

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -40.47, meaning Percheron Therapeutics Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-40.47

Stock Splits

Percheron Therapeutics Ltd's most recent stock split took place on March 19, 2026 with a 75:77 split ratio.

Last Split Date3/19/2026
Split Ratio75:77